Skip to main content

Market Overview

'Attractive Entry Points' In WebMD And Everyday Health Following Clinton's Sell-Off Plan

Share:
'Attractive Entry Points' In WebMD And Everyday Health Following Clinton's Sell-Off Plan

  • Cowen believes that the selloff in WebMD Health Corp. (NASDAQ: WBMD) and Everyday Health Inc (NYSE: EVDY) following Hillary Clinton’s drug pricing plan is overdone.
  • If implemented, the plan could serve to reduce the advertising budgets of many pharma companies.
  • Cowen’s long-term bullish outlook for WebMD and Everyday Health is unaffected by Clinton’s plan.
  • Shares of WebMD and Everyday Health have taken a nosedive in recent days on fears and uncertainty surrounding Democratic presidential frontrunner Hillary Clinton’s new prescription drug price capping plan.

    Despite the fears, Cowen and Company analyst Charles Rhyee sees the drop as a buying opportunity for both names and believes that Clinton’s plan could end up serving as an important catalyst in the pharmaceutical industry’s transition to digital advertising.

    Related Link: What Does Hillary Clinton Have Planned For Biotech?

    Ad Budgets In Jeopardy

    A major part of Clinton’s plan includes revoking pharma companies’ ability to write off consumer-directed advertising for tax purposes. In addition to eliminating this privilege, Clinton’s plan also calls for a greater percentage of revenue to be spent on research and development.

    According to Rhyee, the end result of these changes would be that companies would spend less money on advertising, which could negatively impact brand awareness of name-brand drugs.

    Selloff Overdone

    Rhyee believes that the selloffs in WebMD and Everyday Health are premature and sees several reasons why investors shouldn’t be worried about Clinton’s plan. Primarily, even if Clinton becomes president, the likelihood that her plan would make it through Congress without substantial modifications is extremely low.

    Worst-Case Scenario

    Secondarily, Cowen’s long-term bullish stance on both companies revolves less around advertising and more around the companies’ shift toward digital healthcare services.

    “So, in our view, while it is unlikely the worst case scenario of lower pharma budgets materially affecting WBMD and EVDY’s ad portal business, we see this business becoming naturally less important anyway,” Rhyee explained.

    He added that he sees current levels as “attractive entry points” for both stocks.

    Disclosure: The author holds no position in the stocks mentioned.

    Image Credit: By State Dept Image by Michael Gross [Public domain], via Wikimedia Commons

    Latest Ratings for WBMD

    DateFirmActionFromTo
    Jul 2017Raymond JamesDowngradesOutperformMarket Perform
    Jul 2017SunTrust Robinson HumphreyDowngradesBuyHold
    Mar 2017Cowen & Co.DowngradesOutperformMarket Perform

    View More Analyst Ratings for WBMD

    View the Latest Analyst Ratings

     

    Related Articles (WBMD + EVDY)

    View Comments and Join the Discussion!

    Posted-In: Analyst Color Biotech Long Ideas Health Care Politics Analyst Ratings Trading Ideas General Best of Benzinga

    Latest Ratings

    StockFirmActionPT
    SEDGB of A SecuritiesMaintains411.0
    PTLOPiper SandlerMaintains28.0
    AOUTLake StreetMaintains26.0
    RAPTPiper SandlerMaintains52.0
    OCXLake StreetMaintains6.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    SPAC
    Everything you need to know about the latest SPAC news.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com